UBS Group’s First Trust Indxx Medical Devices ETF MDEV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$364 Buy
19
+10
+111% +$189 ﹤0.01% 9894
2026
Q1
$171 Buy
+9
New +$184 ﹤0.01% 10055
2025
Q2
Sell
-790
Closed -$15.9K 10613
2025
Q1
$15.9K Buy
790
+130
+20% +$2.74K ﹤0.01% 8374
2024
Q4
$13.6K Sell
660
-126
-16% -$2.7K ﹤0.01% 8135
2024
Q3
$17.5K Buy
786
+723
+1,148% +$15.1K ﹤0.01% 7446
2024
Q2
$1.25K Sell
63
-32
-34% -$654 ﹤0.01% 8614
2024
Q1
$2.03K Buy
+95
New +$1.96K ﹤0.01% 7992
2023
Q4
Sell
-100
Closed -$1.8K 9660
2023
Q3
$1.8K Buy
+100
New +$1.97K ﹤0.01% 7827
2023
Q1
Sell
-247
Closed -$4.64K 10042
2022
Q4
$4.64K Buy
247
+240
+3,429% +$4.29K ﹤0.01% 9304
2022
Q3
$0 Buy
7
+2
+40% +$37 ﹤0.01% 10696
2022
Q2
$0 Buy
+5
New +$99 ﹤0.01% 10675
2022
Q1
Sell
-7
Closed 10635
2021
Q4
$0 Buy
+7
New +$181 ﹤0.01% 10515

Other funds holding MDEV

UBS Group's MDEV Position: Q2 2026 in Review

UBS Group increased its First Trust Indxx Medical Devices ETF (MDEV) stake by 111% in Q2 2026, buying an estimated $189 and bringing the position to 19 shares worth $364. The position accounts for ﹤0.01% of the portfolio, ranked #9894.

UBS Group first reported a position in MDEV in Q4 2021 and has held it in 12 quarters since. The position peaked at $17.5K in Q3 2024. 6 funds tracked by Wall St. Rank hold MDEV as of Q2 2026.

  • UBS Group held 19 shares of First Trust Indxx Medical Devices ETF worth $364 as of Q2 2026.
  • UBS Group bought 10 First Trust Indxx Medical Devices ETF shares in Q2 2026, an estimated $189.
  • First Trust Indxx Medical Devices ETF made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9894 holding.
  • UBS Group first reported a position in First Trust Indxx Medical Devices ETF in Q4 2021 and has held it in 12 quarters since.
  • UBS Group's First Trust Indxx Medical Devices ETF position peaked at $17.5K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held First Trust Indxx Medical Devices ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.